

Industry accelerates R&D of innovative antibody drugs

26 March 2021 | News

GenScript Signs a Strategic Partnership with the Theragen Etex and MedPACTO for Therapeutic Antibody Drug development



A global leading biotech company GenScript Biotech Corporation has announced that the Company has entered into a strategic partnership with the Theragen Etex, a South Korea-based comprehensive pharmaceutical and biotechnology group providing outstanding genetic analysis services and progressing personalized new drug development and MedPACTO, an innovative drug discovery and development company based in South Korea commencing an in-depth cooperation for the discovery, development and production antibody drugs through facilitating the transformation of drugs with clinical value from high potential scientific research projects.

This agreement allows three parties to take advantage of the tremendous strength and talent of the scientific research platform in GenScript's in the area of Antibody drugs development.

This in turn will leverage the development of a one-stop technical platform to accelerate the R&D and industrialization of innovative antibody drugs.

Under the agreement, the three companies will strategically align themselves with development processes such as finding, manufacturing, and clinical trials of candidate substances for antibody treatments, and related research and service projects.

GenScript will offer high-quality one-stop platform services of the discovery, development and production antibody drugs, which would be required for MedPACTO and Theragen Etex. MedPACTO will push for cooperation on a number of new pipelines, including the targeted antibody treatment "MA-B2", based on its independently identified cancer-transfer-related protein "BAG2".

Theragen Etex plans to jointly develop antibodies related to chronic inflammatory diseases such as pancreatic cancer and Crohn's disease based on amino acid transporters discovered through genetic analysis.